Immunotherapy for liver cancer: who it may suit and what to watch for

How immunotherapy helps in HCC

Checkpoint inhibitors release some of the brakes that prevent immune cells from attacking cancer. In HCC, they are commonly used as part of a combination. The aim is to control the cancer throughout the body, including disease that cannot be managed by a local procedure alone.

Ask how the proposed combination differs from a targeted tablet and what makes it suitable for your treatment stage. The discussion should be tied to the exact diagnosis and prior medicines. Treatments for bile duct cancer or liver metastases from another organ follow different pathways.

Sources and references: [1]

Which combinations may be discussed

Atezolizumab with bevacizumab combines an immune checkpoint inhibitor with a drug that blocks a blood vessel growth pathway. Durvalumab with tremelimumab combines two immune approaches. Nivolumab with ipilimumab received a US first-line HCC approval in 2025.

These are examples with evidence in defined settings. A specialist should explain the proposed regimen's role, its local indication and the alternative if one component is unsuitable. The names alone do not reveal the monitoring, infusion schedule or likely effect on daily life.

Sources and references: [1] [2]

Why liver function still comes first

The liver may already be affected by cirrhosis, hepatitis or extensive cancer. Many major immunotherapy trials enrolled patients with preserved liver function. The clinician therefore assesses laboratory results, abdominal fluid and other signs of reserve before recommending a regimen.

Ask how the team will distinguish treatment-related liver inflammation from worsening cirrhosis, viral hepatitis or tumor progression. These can require different responses. A clear baseline makes later changes easier to interpret and helps decide when treatment should be paused.

Sources and references: [1] [3]

The extra checks before bevacizumab

Bevacizumab can increase bleeding concerns, which matters in patients with portal hypertension and enlarged veins in the esophagus or stomach. Assessment and management of these varices are part of considering this combination. Blood pressure and other relevant health factors also need review.

Tell the team about vomiting blood, black stools, recent procedures and medicines that affect clotting. Ask whether an endoscopy or further treatment is needed before starting. This allows the team to compare a bevacizumab-containing regimen with alternatives on a sound basis.

Sources and references: [1]

Discuss autoimmune disease and organ transplantation

Immune checkpoint treatment can worsen some autoimmune conditions and can threaten a transplanted organ. A history of autoimmune disease or an organ transplant therefore needs a specific discussion, including the medicines currently used to control immunity.

The decision may require more than one specialty. Ask what complication the team is most concerned about and how it would be managed. If immunotherapy is unsuitable, targeted therapies or another treatment approach may still be considered according to liver function and disease setting.

Sources and references: [3] [1]

Report new symptoms before the next infusion

Immune-related inflammation can affect the bowel, lungs, liver, skin or hormone-producing glands. Persistent diarrhea, a new cough or breathlessness, jaundice, marked weakness or unusual headaches deserve prompt contact with the treating team. Symptoms can also appear after treatment has been held or stopped.

Keep the treatment names with you and tell clinicians elsewhere that you have received immunotherapy. Ask for the unit's urgent instructions. Significant new symptoms may need testing, a treatment pause and medicines to control inflammation; the correct response depends on the organ involved.

Sources and references: [3]

What response and tolerability checks look like

The team follows scans, liver blood tests, other safety tests and your symptoms. Ask when imaging is planned and which changes would support continuing the regimen. AFP can contribute information in some patients but is assessed together with the rest of the picture.

Keep a simple record of bowel changes, breathing symptoms, fatigue and medicines taken between visits. This gives the team more useful information than trying to remember several weeks of symptoms at an infusion appointment.

Sources and references: [1] [3]

Organizing an immunotherapy review in Shanghai

A liver cancer service such as Zhongshan Hospital is a relevant Shanghai resource for reviewing systemic options. Bring the diagnosis, latest images, liver tests, hepatitis history, endoscopy results if available and any autoimmune or transplant records.

EastMedGo can help prepare the appointment inquiry and clarify the receiving service's record requirements. If treatment has already started, include the exact drugs, infusion dates and adverse effects. We can help coordinate the consultation and discuss logistics around the monitoring schedule proposed by the clinical team.

Sources and references: [4]

Common questions